|
Dec 4
|
1 Monster Dividend Stock Growth Investors Should Load Up On Right Now
|
|
Dec 4
|
Is Eli Lilly and Company's (NYSE:LLY) 44% ROE Better Than Average?
|
|
Dec 4
|
Eli Lilly extends tender offer deadline for Point Biopharma shares on low participation
|
|
Dec 4
|
UPDATE 3-Eli Lilly extends tender offer deadline for Point Biopharma shares on low participation
|
|
Dec 4
|
Career advice from the CFOs of Dell, Eli Lilly, and Marriott—3 women who have each spent 20-plus years climbing the ladder at one company
|
|
Dec 4
|
Lilly cancer drug cleared by FDA for expanded leukemia, lymphoma use
|
|
Dec 4
|
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
|
|
Dec 4
|
Pfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II
|
|
Dec 3
|
3 No-Brainer Growth Stocks to Buy in December
|
|
Dec 2
|
I’m ‘trying to be not stupid, instead of very intelligent’: Charlie Munger once revealed the 1 key thing to make ‘big money’ in the stock market — 3 top plays that take full advantage of it
|
|
Dec 2
|
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
|
|
Dec 2
|
5 Top Stocks to Buy Before 2024
|
|
Dec 1
|
US FDA gives second approval to Eli Lilly's drug for type of blood cancer
|
|
Dec 1
|
Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
|
|
Dec 1
|
UPDATE 1-US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy
|
|
Dec 1
|
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
|
|
Dec 1
|
Weight-Loss Stocks Are Getting Pricey. Time to Worry About a Bubble?
|
|
Dec 1
|
1 Underrated Reason to Buy Eli Lilly Stock
|
|
Dec 1
|
Pfizer drops plan for twice-daily obesity pill due to side effects
|
|
Dec 1
|
December Looks Great For Investors Who Own 9 Stocks
|